Analysts expect Turn Therapeutics Inc. to report revenue of 471,347.50 for Q4 26, against a range of 435,754.16 to 506,940.84.
| Metric | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | 506,940.84 | 1.02 M | 1.01 M | 1.13 M | 2.16 M | 3.03 M | 3.03 M | 3.17 M | |||||||||
| Low Estimate | 435,754.16 | 957,748.07 | 830,941.42 | 929,385.30 | 1.91 M | 2.56 M | 2.61 M | 2.60 M | |||||||||
| Consensus Estimate | 471,347.50 | 988,967.81 | 919,648.91 | 1.03 M | 2.04 M | 2.79 M | 2.82 M | 2.89 M |
Analysts expect Turn Therapeutics Inc. to report earnings per share of -0.02 for Q2 26, against a range of -0.02 to -0.02. The most recent reported quarter, Q1 26, came in at -0.03, a 50.0% miss against the -0.02 consensus.
| Metric | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.07 | -0.11 | -0.03 | - | - | - | - | - | - | - | - | |||||||||||
| High Estimate | - | -0.05 | -0.02 | -0.02 | -0.03 | -0.08 | -0.05 | -0.06 | -0.05 | -0.13 | -0.09 | |||||||||||
| Low Estimate | - | -0.05 | -0.02 | -0.02 | -0.03 | -0.10 | -0.05 | -0.06 | -0.07 | -0.15 | -0.11 | |||||||||||
| Consensus Estimate | - | -0.05 | -0.02 | -0.02 | -0.03 | -0.09 | -0.05 | -0.06 | -0.06 | -0.14 | -0.10 |